tbuckley/cabot-search huggingface dataset:
PROPRIETARY MEDICINES AND THEIR ABUSES.
Authors: GEORGE DOCK
Journal: JAMA (1906)

Proprietary medicines are substances which some one has an exclusive right to make or sell for medicinal purposes. The exclusive right may depend on secret methods of manufacture, or on a patent on the method of preparation, as in Germany, or on process and substance both, as in America, or on a copyright on the substance. A patent on the name, or a copyright, is one of the most effective methods of acquiring and maintaining exclusive rights in the case of medicines whose virtues are fictitious, though secrecy is in some cases equally effective, for a time. Proprietary medicines are not either good or bad by reason of their origin. In the language of the day, none are "ethical" or "unethical"<i>per se</i>. The possibility of greatest danger occurs among secret preparations and depends partly on the fact that secrecy regarding a remedy may have more serious consequences than secrecy
Diagnosing Lymphomatosis Cerebri—Reply
Authors: Kimmo J. Hatanpaa, Weina Chen
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
House dust mite-specific IgA2 is associated with protection against eczema in allergic patients
Authors: G. den Hartog, R. J. J. van Neerven, J. D. Boot, A. P. H. Jansen, H. F. J. Savelkoul
Journal: Allergy (2015)

Upon inhalation, house dust mite (HDM) allergens are deposited at the nasal and oral mucosa, where IgA is produced abundantly. IgA subclasses have been linked to protection against respiratory allergy previously. It is currently not known whether and how the human IgA subclasses IgA1 and IgA2 contribute to the clinical status of house dust mite-allergic patients. Saliva and serum samples were collected, and HDM-specific, IgE, IgG4, IgA1 and IgA2 levels were determined. HDM-specific levels of IgA in serum were similar to levels measured in nonallergic controls, but HDM-specific levels of IgA2 in saliva were decreased in allergic subjects. HDM-allergic patients who suffered from rhinitis and eczema showed a significant decrease in IgA2-levels compared to patients who suffered from rhinitis only. Taken together, our findings indicate that HDM-specific IgA2, but not IgA1, levels in serum and saliva are reduced in HDM-allergic patients suffering from eczema.
Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials.
Authors: F. Andre, M. Delorenzi, A. Goubar, M. Lacroix, C. Desmedt, V. Scott, C. Sotiriou, M. Mathieu, S. Delaloge, L. Pusztai
Journal: Journal of Clinical Oncology (2010)

550 Background: There is a need to identify predictive biomarkers for the efficacy of anthracyclines (A)-based chemotherapy (CT) in order to better tailor CT regimen. Methods: The project included two neoadjuvant (discovery phase) and one adjuvant (validation phase) trials evaluating the efficacy of A without taxanes. In the IGR-MDACC study, 24 patients were selected to have presented a pathologic complete response (pCR) to A-based CT. These patients were matched on ER expression with 26 patients presenting a chemoresistant disease (RD). These 50 samples were profiled on Affymetrix U133A. This dataset aimed at discovering a new pathway predictive for A efficacy. The candidate pathway (interferon response) was then tested in TOP-trial (n = 149). The leader biomarker (MX1) of the predictive pathway was then assessed in a tissue microarray (TMA) by IHC (mAb clone AM39). This TMA included primary tumor from 823 patients randomized between A-based CT and no CT between 1988 and 1995 (72% of the trial population). Results: In the IGR-MDACC dataset, the Interferon metagene (MX1) (AUC = 0.72, [0.57-0.86], pfdr = 0.02), and proliferation (TPX2) metagene (AUC = 0.71, [0.55-0.85], pfdr = 0.02) scores were associated with a higher likelihood of pCR. The TOP dataset confirmed that interferon-response was associated with a higher likelihood of pCR (AUC:0.61, [0.47-0.75], p = 0.06). Myxovirus Resistance 1 (MX1) protein was expressed in 93 out of 823 patients (11%) included in the adjuvant trial. MX1 expression was predictive for the efficacy of A-based adjuvant CT (ratio for interaction = 0.4, p = 0.05). Adjuvant A-based CT was associated with a decreased risk of death in MX1-expressing (Hazard ratio: 0.43, 95%CI: 0.18-1.01) but not in MX1-negative BC (HR = 0.99, 95% CI: 0.74-1.33). ER expression was not predictive for treatment efficacy on OS (interaction test, p = 0.11). Conclusions: This study suggests that MX1 expression could predict efficacy of A-based CT. This study is consistent with recent reports suggesting a strong interaction between A efficacy and immune function (Apetoh, Nat Med, 2007, Denkert, J Clin Oncol, 2010). No significant financial relationships to disclose.
Recurrent activating mutations of CD28 in peripheral T-cell lymphomas
Authors: J Rohr, S Guo, J Huo, A Bouska, C Lachel, Y Li, P D Simone, W Zhang, Q Gong, C Wang, A Cannon, T Heavican, A Mottok, S Hung, A Rosenwald, R Gascoyne, K Fu, T C Greiner, D D Weisenburger, J M Vose, L M Staudt, W Xiao, G E O Borgstahl, S Davis, C Steidl, T McKeithan, J Iqbal, W C Chan
Journal: Leukemia (2015)
Abstract 19961: Factors Associated with Glucose Intolerance and Abnormal Lipid Metabolism in Fontan Patients
Authors: Clara Kurishima, Kei Inai, Seiji Asagai, Hideaki Senzaki, Toshio Nakanishi
Journal: Circulation (2014)

Background:  Multi-organs dysfunctions including glucose intolerance has been reported in young adults after the Fontan operation.  We investigated factors associated with abnormalities in glucose tolerance and lipid metabolism in the chronic phase after the Fontan operation.   Methods:  We studied 51 patients (mean 25.0, range 16-51 years old) after the Fontan operation who were hospitalized for catheter examination in our hospital. We excluded patients under 16 years of age.  HbA1c was used for the assessment of glucose tolerance, and total cholesterol (T-Cho) and triglyceride (TG) for the assessment of lipid metabolism.   Results:  Mean HbA1c value was 5.8± 4.5%, and 77% of patients had abnormal HbA1c value higher than the normal upper value of 5.6%. In addition, high TG and T-Cho were recognized in 11% and 15% of patients, respectively. HbA1c had a negative correlation with cardiac index(CI)(P   Discussions:  There is a high incidence of impaired glucose tolerance and abnormal lipid metabolism in patients after the Fontan operation. Both were closely associated with the severity of heart failure status of Fontan circulation. In addition, impaired glucose tolerance may be an important pathophysiology underlying vascular endothelial dysfunction often observed in Fontan patients, and may be an important therapeutic target to improve Fontan physiology.
EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models
Authors: L. Danielle Johnston, Sarah Knutson, Natalie Warholic, Christine R Klaus, Tim J. Wigle, Dorothy Iwanowicz, Bruce A. Littlefield, Margaret Porter Scott, Jesse J Smith, Mikel P Moyer, Robert A. Copeland, Roy M. Pollock, Kevin W Kuntz, Heike Keilhack, Alejandra Raimondi
Journal: Blood (2013)
Prevalence of Diabetes and Diabetic Nephropathy in a Large U.S. Commercially Insured Pediatric Population, 2002–2013
Authors: Lin Li, Susan Jick, Stefanie Breitenstein, Alexander Michel
Journal: Diabetes Care (2015)

OBJECTIVE To estimate the prevalence of diabetes and diabetic nephropathy in a large population of U.S. commercially insured patients aged &amp;lt;18 years from 2002 to 2013. RESEARCH DESIGN AND METHODS Using the U.S. MarketScan Commercial Claims and Encounters Database, we identified 96,171 pediatric patients with diabetes and 3,161 pediatric patients with diabetic nephropathy during 2002–2013. We estimated prevalence of pediatric diabetes overall, by diabetes type, age, and sex, and prevalence of pediatric diabetic nephropathy overall, by age, sex, and diabetes type. RESULTS The annual prevalence of diabetes in the whole pediatric population increased from 1.86 to 2.82 per 1,000 during 2002–2013: 1.48 to 2.32 per 1,000 for type 1 diabetes and 0.38 to 0.67 per 1,000 for type 2 diabetes in 2002–2006 and then 0.56 to 0.49 per 1,000 thereafter. The annual prevalence of diabetic nephropathy in pediatric patients with diabetes increased from 1.16 to 3.44% for all cases and 0.83 to 2.32% for probable cases only in 2002–2013. Prevalence of diabetes and diabetic nephropathy was highest in patients aged 12 to &amp;lt;18 years. While prevalence of type 1 diabetes was higher in male than in female youth, prevalence of type 2 diabetes and diabetic nephropathy was higher in female than in male youth. There was no difference in prevalence of diabetic nephropathy by diabetes type. CONCLUSIONS The prevalence of diabetes and diabetic nephropathy increased in the U.S. MarketScan commercially insured pediatric population from 2002 to 2013. The prevalence of diabetes and diabetic nephropathy markedly increased starting at age 12 years.
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Authors: Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, Robert Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo E. Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood (2015)
Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting
Authors: Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, Abhay R. Shelke
Journal: Journal of the National Comprehensive Cancer Network (2004)

Although emesis can be considered a reflex to clear toxins from the body and involves mostly lower brain structures, nausea's purpose appears to be a warning signal to the individual to not engage in behaviors that he or she was doing at the time. As such, it involves the functioning of cognition and memory from higher developed neural structures. Given this, it should not be surprising that biobehavioral factors are important in predicting and controlling nausea. This article reviews the individual characteristics that are clinically useful in predicting which patients will have an increased probability of experiencing nausea or emesis during chemotherapy treatment, and also briefly review psychologic and biobehavioral treatments that can be useful in managing chemotherapy-related nausea.
Ten years of <scp>DNA</scp> diagnostics of epidermolysis bullosa in the Czech Republic
Authors: L. Kopečková, H. Bučková, J. Kýrová, R. Gaillyová, J. Němečková, B. Jeřábková, K. Veselý, K. Stehlíková, L. Fajkusová
Journal: British Journal of Dermatology (2015)

Epidermolysis bullosa (EB) is a heterogeneous group of
inherited skin disorders characterized by blister formation.
Classification of patients with EB begins with their separation
into one of the four major EB groups, based on the level to
which blisters develop: EB simplex (EBS), junctional EB (JEB),
dystrophic EB (DEB) and Kindler syndrome. The next level of
subclassification takes into account the clinical features
present in a given patient, most notably the distribution and
severity of cutaneous and extracutaneous disease involvement.
Abstract #5542: Down-regulation of survivin enhances sensitivity to BPR0L075 in human cancer cells via caspase-independent mechanisms
Authors: Chun Hei Antonio Cheung, Chi-Yen Chang, Hsing-Pang Hsieh, Jang-Yang Chang
Journal: Cancer Research (2009)

BPR0L075 [6-methoxy-3-(39,49,59-trimethoxy-benzoyl)-1H-indole] is a novel anti-mitotic compound. We pervious have demonstrated that this compound could inhibit tubulin polymerization and induces mitochondrial-dependent apoptosis in various human cancer cells with different multi-drug resistance (MDR) status (Kuo  et al ., Cancer Research, 2004). Over-expression of an anti-apoptotic molecule, survivin, causes drug-resistance in various cancers. Survivin inhibits apoptosis by interfering caspase-3 and promotes cell growth by stabilizing microtubule networks. Here, we determined the effects of down-regulation of survivin in BPR0L075 (L075) treatment. Western blot analysis and RT-PCR show that survivin expression was up-regulated in both human KB and HONE-1 cancer cells in response to L075 treatment. Down-regulation of survivin by siRNA induced hyper-sensitivity to L075 in KB and re-stored sensitivity to L075 in KB-derived L075-resistant KB- L30  cancer cells. At the molecular level, western blot analysis and immunofluorescence microscopy reveal that down-regulation of survivin induced changes in microtubule dynamics in both KB and KB- L30  cells. Surprisingly, down-regulation of survivin did not enhance the activity of caspase-3 in L075 therapy. Instead, down-regulation of survivin induced translocation of the apoptosis-inducing factor (AIF) from cytoplasm to nucleus. In summary, down-regulation of survivin improved drug sensitivity to L075 in both KB and L075-resistant KB- L30  cancer cells, through a tubulin-dependent and caspase-independent mechanism. Our data suggest that combining BPR0L075 and survivin inhibitor may give better clinical outcome than the use of BPR0L075 monotherapy in future clinical trials.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5542.
Close the loop to show patients the value of taking part in research
Authors: Paul Wicks
Journal: BMJ (2015)

Darzi describes challenges to overcome in persuading sceptical members of the public to share their medical records for research.1 To inspire confidence we must close the value loop in patients’ minds between what their data mean, what data can do, and what has been done with their data. One example of a virtuous altruism loop occurs …
Freewheelin’ scientists: citing Bob Dylan in the biomedical literature
Authors: Carl Gornitzki, Agne Larsson, Bengt Fadeel
Journal: BMJ (2015)

Carl Gornitzki and colleagues examine how far medical scientists are under his spell 

In September 2014 it emerged that a group of scientists at the Karolinska Institute in Sweden had been sneaking the lyrics of Bob Dylan into their papers as part of a long running bet. The story, originally published in the house magazine KI-Bladet , quickly went viral—spreading from the local Swedish press to international media such as the Guardian and Washington Post .1 2 It all started in 1997 with a review in Nature Medicine entitled “Nitric oxide and inflammation: the answer is blowing in the wind.”3 A local phenomenon was thus revealed, but was this Dylan citing unique to the Karolinska Institute? We decided to investigate how Dylan’s lyrics are cited in the biomedical literature.

We used a list of all Dylan’s song and album titles downloaded from bobdylan.com to do a search using Medline in May 2015. In addition, we searched for truncated versions of a selection of the most popular Dylan songs to find modified titles,4 such as “Knockin’ on pollen’s door: live cell …
Mineotaur: a tool for high-content microscopy screen sharing and visual analytics
Authors: Bálint Antal, Anatole Chessel, Rafael E. Carazo Salas
Journal: Genome biology (2015)

High-throughput/high-content microscopy-based screens are powerful tools for functional genomics, yielding intracellular information down to the level of single-cells for thousands of genotypic conditions. However, accessing their data requires specialized knowledge and most often that data is no longer analyzed after initial publication. We describe Mineotaur ( http://www.mineotaur.org ), a open-source, downloadable web application that allows easy online sharing and interactive visualisation of large screen datasets, facilitating their dissemination and further analysis, and enhancing their impact.
Abstract MP60: Associations of Socio-Economic and Access to Care Factors With Inpatient and Outpatient Heart Failure. The Aric Study
Authors: Carmen Cuthbertson, Anna Kucharska-Newton, Mehul Patel, Ricky Camplain, Randi Foraker, Lisa Wruck, Aaron Folsom, Nicole Puccinelli-Ortega, Kunihiro Matsushita, Gerardo Heiss
Journal: Circulation (2015)

BACKGROUND:  Little is known about the burden of heart failure (HF) managed in outpatient settings and of the characteristics that influence the degree to which HF is diagnosed in outpatient venues predating a hospitalization. We hypothesized that access to care and socio-economic contextual factors relate to patient ascertainment of incident HF in outpatient vs inpatient settings.   METHODS:  We created an open cohort of consecutive fee-for-service CMS Medicare beneficiaries (2003 - 2006) residing in the four epidemiologic surveillance areas of the Atherosclerosis Risk in Communities (ARIC) Study. Using a 24 month look-back period we classified incident inpatient HF (IP HF) diagnoses as the first observed HF hospitalization (ICD-9 code 428.xx in any position). Incident outpatient HF (OP HF) diagnoses were defined as two outpatient HF encounters within 365 days, with a 12 month look-back period. Three contextual factors were characterized at the level of zip code tabulation area: number of primary care physicians per 1,000 population (grouped by tertiles), the proportion of the population living in a medically underserved area (MUA) (any vs. none), and the proportion of the population living in poverty (high defined as 10% or more). Associations of contextual factors with incident IP HF or OP HF diagnoses were estimated as incidence rate ratios (IRR, 95% CI) using Poisson generalized linear models. We estimated separate models for each contextual factor while controlling for the other contextual factors, age, sex, race, and ARIC community.   RESULTS:  The study population included 106,585 consecutive fee-for-service beneficiaries (40% male, median age 75 years, 11.5% non-white). We observed 3,348 incident IP HF diagnoses and 1,050 OP HF diagnoses over 310,689 person-years of follow-up (age-adjusted rates per 1,000 person-years: IP HF 15.8 (95% CI 15.0, 16.6); OP HF rate 4.7 (4.4, 5.2). The adjusted rates of IP HF diagnosis were similar across strata of physician density, while rates of OP HF diagnoses were higher in low physician density areas compared to high physician density areas (IRR 1.23, (1.17, 1.29). Rates of IP HF and OP HF diagnoses were higher in high poverty areas compared to low poverty areas (IP HF IRR 1.23 (1.10, 1.38); OP HF IRR 1.26 (1.03, 1.55)). In areas with any MUA population, IP HF rates were higher as compared to areas with no MUA (IRR 1.10 (1.01, 1.21)) but no difference was found for OP HF rates.   CONCLUSION:  Contextual factors pertaining to low access to care and low socio-economic status were associated with differences in the rate of inpatient versus outpatient HF diagnoses among CMS Medicare beneficiaries in four ARIC Study communities. Further research is needed to understand the effect of observed differences in the clinical location of HF diagnosis on outcomes.
Positive appraisal style: The mental immune system?
Authors: Laura Luyten, Yannick Boddez, Dirk Hermans
Journal: Behavioral and Brain Sciences (2015)

Abstract Instead of converging to one, all-embracing resilience mechanism – that is, positive appraisal style – we encourage complementary research strategies, exploring both vulnerabilities and resilience factors, much like the biomedical sciences combine insights from pathophysiology and immunology. Furthermore, we argue that research with a strong focus on one central resilience mechanism may overlook or undervalue other processes that can aid in maintaining mental health.
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Authors: Lecia V. Sequist, Zofia Piotrowska, Matthew J. Niederst, Rebecca S. Heist, Subba Digumarthy, Alice T. Shaw, Jeffrey A. Engelman
Journal: JAMA Oncology (2015)

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving RociletinibThird-generation EGFR tyrosine kinase inhibitors (TKIs) that block activating EGFR mutations and the T790M resistance mutation yield marked responses among patients with EGFR mutation-positive lung cancer and acquired resistance to initial TKIs. 1,2Osimertinib (formerly AZD9291) was recently approved by the US Food and Drug Administration, and rociletinib (formerly CO-1686) is under regulatory consideration.Little is known about using third-generation EGFR inhibitors sequentially.Methods | This cohort includes all patients exposed to more than 1 third-generation EGFR TKI at our center.Patients were enrolled in the TIGER-X phase 1/2 trial of rociletinib (NCT01526928) and subsequently on the AURA phase 1/2 trial of osimertinib (NCT01802632). 1,2Each study required screening biopsy specimens to assess T790M status; depending on enrollment date, T790M-positive status may not have been required.We report both prospectively assessed responses, where independent target lesions were chosen for each study, and retrospective longitudinal responses, which were measured across both therapies using consistent target lesions for patients who transitioned directly from rociletinib to osimertinib.While eligibility criteria for AURA allowed prior treatment with other third-generation TKIs, the TIGER-X trial did not.
Australasian College of Sports Physicians—position statement: the place of mesenchymal stem/stromal cell therapies in sport and exercise medicine
Authors: Hamish Osborne, Lynley Anderson, Peter Burt, Mark Young, David Gerrard
Journal: British Journal of Sports Medicine (2015)

This Position Statement has been written expressly for members of the Australasian College of Sports Physicians (ACSP); however, it may also be of interest to the wider medical community, sporting organisations, athletes and the general community. It has been informed by a comprehensive review of the scientific literature and the opinions of kindred organisations. This statement outlines the use of mesenchymal stem cell (MSC) therapies in the broad context of Sport and Exercise Medicine, recognising that every medical practitioner should respect: (1) the evidence for the therapeutic use of MSCs and (2) the priority for patient health and welfare.
Treatment of Intracranial Metastatic Esthesioneuroblastoma
Authors: Marc C. Chamberlain
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.1.357 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11773199 Treatment of Intracranial Metastatic Esthesioneuroblastoma Marc C. ChamberlainxMarc C. ChamberlainSearch for articles by this author Show More University of Southern California/Norris Cancer Center, Los Angeles, CA https://doi.org/10.1200/JCO.2002.20.1.357 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology